Table II.
Demographic, clinical and serological characteristics of sarcoidosis patients and healthy controls
| Parameter | Sarcoidosis patients | Healthy individuals | |
|---|---|---|---|
| Demographic data: | |||
| Number | 86 | 50 | |
| Age | Mean ± SD | 48.7 ±10.2 | 39.2 ±11.3 |
| Sex distribution | Women | 64 (74.4%) | 31 (62.0%) |
| Men | 22 (25.6%) | 19 (38.0%) | |
| Clinical parameters: | |||
| Disease activity*** | Acute | 27 (31.4%) | |
| Chronic | 59 (68.6%) | ||
| Organ involved | Lung | 84 (97.7%) | |
| CNS | 14 (16.3%) | ||
| Skin | 4 (4.7%) | ||
| Eye | 8 (9.3%) | ||
| Liver | 1 (1.2%) | ||
| Spleen | 3 (3.5%) | ||
| Lymph node | 7 (8.1%) | ||
| Bone | 2 (2.3%) | ||
| Stomach | 1 (1.2%) | ||
| Parotid gland | 1 (1.2%) | ||
| Bone marrow | 1 (1.2%) | ||
| Ro stage | 0 | 24 (27.9%) | |
| 1 | 30 (34.9%) | ||
| 2 | 28 (32.6%) | ||
| 3 | 4 (4.7%) | ||
| Vitamin D status [mg/l] | < 10 | 38 (44%) | |
| 10–30 | 43 (50%) | ||
| > 30 | 5 (5.8%) | ||
| Therapy | Prednisone | 57 (66.3%) | |
| Methotrexate | 4 (4.7%) | ||
| Prednisone + methotrexate | 2 (2.3%) | ||
| Without therapy | 23 (26.7%) | ||